Clinical Trial Update: Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE) [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial evaluating ZYN002 transdermal gel in children and adolescents with 22q11.2 Deletion Syndrome has completed enrollment and results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• 22q11 Deletion Syndrome

Drugs mentioned

• ZYN002

Snippet

Sponsor: Harmony Biosciences Management, Inc. | Conditions: 22Q11.2 Deletion Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2026-03-09